Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Trametinib Sensitivity is Defined by a Myeloid Differentiation Profile in Acute Myeloid Leukemia.

Drugs in R&D - 1 Sept 2024

Quesnel-Vallières Mathieu, Schultz David C, Orlenko Alena, Lo Yancy, Moore Jason, Ritchie Marylyn, Roth David, Carroll Martin, Barash Yoseph, Lynch Kristen W, Cherry Sara

Abstract excerpt

BACKGROUND AND OBJECTIVE: Acute myelogenous leukemia (AML) is a common blood cancer marked by heterogeneity in disease and diverse genetic abnormalities. Additional therapies are needed as the 5-year survival remains below 30%. Trametinib is a mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor that is widely used in solid tumors and also in tumors with activating RAS mutations. A subset of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cell Differentiation

Share to Leukemia, Myeloid, Acute

Share to Protein Kinase Inhibitors

Share to Pyridones

Share to Pyrimidinones

Share to Transcriptome

Source

Open in PubMed Open full text

Identifiers

PMID: 39316279
DOI: 10.1007/s40268-024-00491-5
PMCID: PMC11456044

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Trametinib Sensitivity is Defined by a Myeloid Differentiation Profile in Acute Myeloid Leukemia.PMID 39316279Read ↗

Mutation Patterns Predict Drug Sensitivity in Acute Myeloid LeukemiaSemantic proximity Read ↗

T Cell-Mediated Tumor Killing Sensitivity Gene Signature-Based Prognostic Score For Acute Myeloid LeukemiaSemantic proximity Read ↗

Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.Semantic proximity Read ↗

A Rapid Gene Expression Profiler Classifies AML Tumor Responsiveness to Standard TherapiesSemantic proximity Read ↗

Mutation Patterns Predict Drug Sensitivity in Acute Myeloid Leukemia.Semantic proximity Read ↗

Clinico-genomic characterization of RAS-mutant acute myeloid leukemia.Semantic proximity Read ↗

Machine learning from the CARDAMON trial identifies a carfilzomib-specific mutational response signatureSemantic proximity Read ↗

Monocytic Differentiation and AHR Signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid LeukemiaSemantic proximity Read ↗

RAS pathway activation drives clonal selection and monocytic differentiation in FLT3 and BCL2 inhibitor resistanceSemantic proximity Read ↗

Clinical implications of RAS mutations in AML: prognostic significance is based upon the involved gene and mutation complexity.Semantic proximity Read ↗

Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature.Semantic proximity Read ↗

Mechanism of response to FHD-286 and decitabine combination in patients with advanced myeloid malignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.